Literature DB >> 20087335

Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases.

Alessandro Zerbi1, Massimo Falconi, Guido Rindi, Gianfranco Delle Fave, Paola Tomassetti, Claudio Pasquali, Vanessa Capitanio, Letizia Boninsegna, Valerio Di Carlo.   

Abstract

OBJECTIVES: Information on pancreatic endocrine tumors (PETs) comes mostly from small, retrospective, uncontrolled studies conducted on highly selected patients. The aim of the study was to describe the clinical and pathological features of PETs in a prospective, multicenter study.
METHODS: Newly diagnosed, histologically proven, sporadic PETs observed from June 2004 to March 2007 in 24 Italian centers were included in a specific data set.
RESULTS: Two hundred ninety-seven patients (mean age 58.6+/-14.7 years, females 51.2%, males 48.8%) were analyzed. In 73 cases (24.6%), the tumor was functioning (F) (53 insulinomas, 15 gastrinomas, 5 other syndromes) and in 232 (75.4%) it was non-functioning (NF); in 115 cases (38.7%), the diagnosis was incidental. The median tumor size was 20 mm (range 2-150). NF-PETs were significantly more represented among carcinomas (P<0.001). Nodal and liver metastases were detected in 84 (28.3%) and 85 (28.6%) cases, respectively. The presence of liver metastases was significantly higher in the NF-PETs than in the F-PETs (32.1% vs. 17.8%; P<0.05), and in the symptomatic than in the asymptomatic patients (34.6% vs. 19.1%; P<0.005). At the time of recruitment, the majority of patients (251, 84.5%) had undergone surgery, with complete resection in 209 cases (83.3%).
CONCLUSIONS: This study points out the high number of new cases of PETs observed in Italy, with a high prevalence of NF and incidentally discovered forms. The size of the tumor was smaller and the rate of metastasis was lower than usually reported, suggesting a trend toward an earlier diagnosis.

Entities:  

Mesh:

Year:  2010        PMID: 20087335     DOI: 10.1038/ajg.2009.747

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  33 in total

1.  Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases.

Authors:  Alessandro Zerbi; Vanessa Capitanio; Letizia Boninsegna; Claudio Pasquali; Guido Rindi; Gianfranco Delle Fave; Marco Del Chiaro; Riccardo Casadei; Massimo Falconi
Journal:  Langenbecks Arch Surg       Date:  2010-09-21       Impact factor: 3.445

Review 2.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

3.  Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.

Authors:  Mitsuru Sugimoto; Tadayuki Takagi; Takuto Hikichi; Rei Suzuki; Ko Watanabe; Jun Nakamura; Hitomi Kikuchi; Naoki Konno; Yuichi Waragai; Hiroyuki Asama; Mika Takasumi; Hiroshi Watanabe; Katsutoshi Obara; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

4.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

5.  Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.

Authors:  S Chiloiro; F Lanza; A Bianchi; G Schinzari; M G Brizi; A Giampietro; V Rufini; F Inzani; A Giordano; G Rindi; A Pontecorvi; L De Marinis
Journal:  Endocrine       Date:  2017-05-31       Impact factor: 3.633

6.  Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.

Authors:  Yugang Cheng; Hanxiang Zhan; Lei Wang; Jianwei Xu; Guangyong Zhang; Zongli Zhang; Sanyuan Hu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

Review 7.  Practical management and treatment of pancreatic neuroendocrine tumors.

Authors:  Naoko Iwahashi Kondo; Yasuharu Ikeda
Journal:  Gland Surg       Date:  2014-11

8.  Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Authors:  Monica Ter-Minassian; Jennifer A Chan; Susanne M Hooshmand; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Laurie Buchanan; Zhi Rong Qian; Charles S Fuchs; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

Review 9.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

10.  Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.

Authors:  Alessandro Zerbi; Vanessa Capitanio; Letizia Boninsegna; Gianfranco Delle Fave; Claudio Pasquali; Guido Rindi; Davide Campana; Massimo Falconi
Journal:  HPB (Oxford)       Date:  2013-03-08       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.